NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked a research collaboration with the University of Liverpool to use the firm's tools to identify and validate cancer drug targets and biomarkers for personalized cancer therapy and diagnostics.

The partners will utilize Horizon's X-Man cell lines and have access to the firm's panel of over 150 genetically-defined isogenic disease models, said Horizon. The company will work with Michael Clague of the University of Liverpool to identify unique protein biomarker signatures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
14
Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.